objective determine genetic polymorphisms core promoter region gene contribute clinical response leukotriene receptor antagonists methods retrospectively genotyped NUMBER asthmatics mutations gene studies measuring leukotriene receptor antagonist responses studies measured bronchodilator response bronchial hyperresponsiveness adenosine monophosphate measured studies n NUMBER results NUMBER patients genotyped NUMBER homozygous wild type NUMBER heterozygous homozygous mutant significant difference improvements conferred leukotriene receptor antagonists versus placebo forced expiratory volume NUMBER s NUMBER l homozygotes NUMBER l heterozygotes forced flow rate NUMBER NUMBER peak expiratory flow rate NUMBER NUMBER adenosine monophosphate NUMBER fall forced expiratory volume NUMBER s shift shift genotypes conclusion population screening polymorphism aid guiding treatment probably worthwhile addition difference homozygous wild types heterozygotes terms bronchodilator response bronchial hyperresponsiveness leukotriene receptor antagonists NUMBER lipoxygenase placebo controlled wild type mid expiratory NUMBER fold NUMBER fold l s l s l min l min